ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Management of female pattern hair loss

Management of female pattern hair loss
Assess all patients for signs of hyperandrogenism (eg, hirsutism, irregular menses, moderate to severe acne, treatment-refractory adult acne, acanthosis nigricans, or galactorrhea), and pursue hyperandrogenism testing in those with suggestive clinical features. Treatment of associated hyperandrogenism improves outcomes in the subset of patients with hyperandrogenism-associated FPHL and may be sufficient for some patients. Refer to additional UpToDate content on the diagnosis of FPHL for details.
Treatment aims to prevent progression of hair loss and improve hair density to a point that is cosmetically satisfactory for the patient (ie, good response). Initiating treatment prior to extensive hair loss is preferred because responses to treatment are variable and can be incomplete.
Patients may also benefit from adjunctive cosmetic measures that provide the appearance of increased hair coverage on the scalp (eg, hair styling techniques, hair dye, hair fibers, scalp micropigmentation, thickening shampoos, and wigs or other hair prostheses).
LLLT: low-level laser therapy; FPHL: female pattern hair loss.
* We treat most patients with both topical minoxidil and an oral antiandrogen. Treatment with topical minoxidil alone is an alternative initial approach for patients who cannot tolerate or prefer to avoid oral antiandrogenic therapy. Spironolactone is our preferred initial oral antiandrogen based upon data that suggest benefit and the extensive experience with this drug for other indications in females.
¶ Patient preferences about the mode of administration and treatment risks influence selection among these treatments. Refer to additional UpToDate content on the failure of initial therapy for FPHL for details. Some clinicians also use combination oral antiandrogenic therapy (eg, spironolactone and finasteride) when patients fail to respond to a single antiandrogen. However, data to confirm superior efficacy of combination therapy are lacking. We treat most patients with a single oral antiandrogen and reserve combination therapy for occasional, treatment-refractory cases.
Graphic 134317 Version 1.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟